{"abstract": "The study of Zytiga from Johnson & Johnson also showed that it could pose a competitive threat to a rival drug, Provenge from Dendreon.", "web_url": "https://www.nytimes.com/2012/03/09/business/trial-shows-benefit-in-earlier-use-of-zytiga-for-prostate-cancer.html", "snippet": "The study of Zytiga from Johnson & Johnson also showed that it could pose a competitive threat to a rival drug, Provenge from Dendreon.", "lead_paragraph": "Johnson & Johnson said Thursday that its new drug for prostate cancer was effective when used earlier during treatment than it is now, potentially broadening its use and also posing a competitive threat to a rival drug, Dendreon\u2019s Provenge. ", "print_section": "B", "print_page": "2", "source": "The New York Times", "multimedia": [], "headline": {"main": "Trial Shows Benefit in Using Prostate Cancer Drug Early", "kicker": null, "content_kicker": null, "print_headline": "Trial Shows Benefit in Using Prostate Cancer Drug Early", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Research", "rank": 2, "major": "N"}, {"name": "subject", "value": "Prostate Cancer", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Johnson & Johnson", "rank": 4, "major": "N"}], "pub_date": "2012-03-09T00:52:11+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Andrew Pollack", "person": [{"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/253bad15-3c33-57dd-adba-c69c6893d40a", "word_count": 549, "uri": "nyt://article/253bad15-3c33-57dd-adba-c69c6893d40a"}